AbbVie's etentamig shows strong efficacy in late-stage multiple myeloma trial

AbbVie reported positive topline results from the Phase 3 CERVINO trial of etentamig, an investigational treatment for relapsed or refractory multiple myeloma. The trial met its primary efficacy endpoints with the drug demonstrating a 74% objective response rate compared to 45.7% for standard therapies, and a 12-month overall survival rate of 87.9% versus 72% for standard treatments. Etentamig also showed a manageable safety profile with treatment discontinuations due to adverse events at 3.6% compared to 9.6% for standard care. The Independent Data Monitoring Committee recommended unblinding the study based on the strong interim results, and the company plans to engage with global regulatory agencies about next steps.

1. AbbVie reported Phase 3 CERVINO trial topline results on Thursday, September 3, 2026, for etentamig in relapsed or refractory multiple myeloma.
2. The study included 393 patients who had undergone a median of three prior treatment lines, with median follow-up of 11.4 months.
3. Etentamig achieved a 74% objective response rate versus 45.7% for standard therapies, meeting the primary efficacy goal.
4. The 12-month overall survival rate was 87.9% for etentamig versus 72% for standard treatments, though not yet crossing prespecified boundary.
5. Severe grade 3 or 4 infections occurred in 27.7% of the etentamig group versus 19.2% in the standard therapy group.
6. Fatal grade 5 infections were lower for etentamig at 1.5% compared to 3.1% for standard care.
7. Treatment discontinuations due to adverse events were 3.6% for etentamig versus 9.6% for standard therapies.